Project Grant R03CA308660
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $160K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a $592,731 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning May 15, 2026, and concluding April 30, 2031. This award supports a randomized controlled trial to improve prostate cancer screening among Black men in Oklahoma through development and validation of the Prostate Cancer Genius App (PCGA), a smartphone-based mobile health...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $641,419 Project Grant on May 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation and evaluation of a novel positron emission tomography (PET) theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC). The primary deliverable is the first-in-man clinical imaging study of [77Br]Br-WC-DZ, a bromine-77 ligand targeting...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $354,658 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025 through July 31, 2030. This award supports fundamental research investigating subclonal P27 (CDKN1B) loss as a driver of aggressive prostate cancer, with particular focus on understanding health disparities affecting Black or African American males who experience prostate cancer mortality...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $425,088 to The Washington University (Office of Sponsored Research Services) on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The five-year project, with completion scheduled for April 30, 2031, will deliver comprehensive research evaluating lung cancer care delivery and quality outcomes across two distinct Medicare coverage models: Traditional Medicare...
- Federal Grant Award Summary The National Cancer Institute awarded Washington University a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. This research project targets the enhancement of neoantigen cancer vaccine efficacy by investigating the mechanisms through which Type 1 Regulatory (TR1) CD4 T cells suppress antitumor immune responses. The research deliverables include scientific studies designed to...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $399,829 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel research models for investigating sex-based disparities in glioblastoma (GBM). The award, effective July 7, 2025 through June 30, 2027, funds the creation of investigative tools and methodologies to examine how sex chromosomes and sex hormones influence GBM phenotype, proliferation, and...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $355,706 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2025, through May 31, 2030. The award funds fundamental research aimed at understanding the role of RAMS11 (RNA Associated with Metastasis 11), a long noncoding RNA (lncRNA), in non-small cell lung cancer (NSCLC) development and progression. The research addresses a critical knowledge gap in cancer biology...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $604,616 Project Grant to The Johns Hopkins University, effective May 12, 2026 through April 30, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award supports the establishment of the Prostate Cancer Cohort Consortium (PC3), a collaborative epidemiologic initiative designed to improve precision risk stratification and prevention strategies for prostate cancer. The project integrates ten...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $679,290 Project Grant to the University of California, San Francisco (UCSF) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and translate novel hyperpolarized (HP) carbon-13 dual-agent magnetic resonance imaging (MRI) technologies for improved prostate cancer diagnosis and biopsy guidance. The award, effective April 1, 2026, through March 31, 2031, supports research designed to...
- Project Grant Summary Georgetown University received a $663,383 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 1, 2025, to support proactive outreach and streamlined genetic testing initiatives for prostate cancer survivors. The project, extending through July 31, 2030, addresses the critical gap between expanded germline genetic testing guidelines and low testing rates among the nation's over three million...